- Home
- MAN vs TNGX Comparison
MAN vs TNGX Comparison
Compare MAN & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAN | TNGX |
|---|---|---|
| Founded | 1948 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MAN | TNGX |
|---|---|---|
| Price | $28.32 | $16.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $38.50 | $17.50 |
| AVG Volume (30 Days) | 1.5M | ★ 3.5M |
| Earning Date | 04-30-2026 | 06-01-2026 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,957,100,000.00 | $62,384,000.00 |
| Revenue This Year | $5.26 | N/A |
| Revenue Next Year | $3.34 | $13.81 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.58 | ★ 48.29 |
| 52 Week Low | $25.15 | $1.04 |
| 52 Week High | $61.58 | $17.63 |
Technical Indicators
Market Signals| Indicator | MAN | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 74.63 |
| Support Level | $28.26 | $10.90 |
| Resistance Level | $29.26 | N/A |
| Average True Range (ATR) | 1.54 | 1.16 |
| MACD | 0.12 | 0.48 |
| Stochastic Oscillator | 61.44 | 87.92 |
Price Performance
Historical ComparisonAbout MAN ManpowerGroup
ManpowerGroup Inc. is engaged in providing workforce solutions and services. The company provides services that include Recruitment and Assessment, Upskilling, Reskilling, Training and Development, Career Management, Outsourcing, and Workforce Consulting. The reportable segments of the company are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others. The Staffing and Interim segment derives the maximum of the company's revenue. The company derives maximum geographical revenue from the Southern European region.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.